CJC-1295 is a synthetic analogue of growth hormone-releasing hormone (GHRH) that has been extensively studied for its ability to stimulate sustained growth hormone release. It is a cornerstone compound in GH-related peptide research. Below are frequently asked questions about CJC-1295 and Peptides Pharma's vial formulation.
CJC-1295 is a synthetic 30-amino acid peptide analogue of growth hormone-releasing hormone (GHRH). It is designed to provide sustained stimulation of GH release from the pituitary gland. Peptides Pharma CJC-1295 is formulated at >99% purity with a 5 mg dose in a precision vial system.
CJC-1295 binds to the GHRH receptor on pituitary somatotroph cells, stimulating pulsatile GH release. Its modified structure resists enzymatic degradation, resulting in a longer half-life compared to native GHRH, allowing for prolonged GH elevation in research subjects.
CJC-1295 is studied in research related to growth hormone secretion, body composition, sleep quality, metabolic function, bone density, and age-related GH decline. It is one of the primary peptides in growth hormone axis research.
Peptides Pharma CJC-1295 is delivered via a lyophilized vial containing 5 mg in 3 mL. The vial is designed for subcutaneous injection, typically administered in the evening to align with natural GH release patterns. No reconstitution is required.
Peptides Pharma CJC-1295 is manufactured to >99% purity in GMP-certified, ISO 7 cleanroom facilities. Independent HPLC and mass spectrometry testing verify each batch. A Certificate of Analysis is provided with every order.
CJC-1295 pens must be stored refrigerated at 2-8°C, away from direct sunlight. Do not freeze. Shelf life is 24 months under proper storage conditions.
CJC-1295 is frequently studied in combination with Ipamorelin, targeting complementary GH-stimulating pathways. This is research information only and not medical advice.
Each Peptides Pharma CJC-1295 vial provides a full 30-day dosing period. The 5 mg / 3 mL formulation is calibrated for daily dosing over the complete monthly cycle.
CJC-1295 with DAC has an extended half-life through albumin binding. CJC-1295 without DAC (Mod GRF 1-29) produces more natural, pulsatile GH release. Peptides Pharma's formulation is optimised for consistent research activity.
CJC-1295 is legal to purchase in the UK for research purposes. It is not classified as a controlled substance and is not approved as a medicine. Peptides Pharma supplies CJC-1295 strictly for laboratory and research use.
Answers to frequently asked questions about BPC-157 peptide research. Learn about purity, storage, administration, and research applications of Peptides Pharma BPC-157 vials.
10 questionsPRODUCTAnswers to common TB-500 research questions. Learn about Thymosin Beta-4, tissue repair mechanisms, storage, purity, and Peptides Pharma's lyophilized vial format.
10 questionsPRODUCTIpamorelin research FAQ. Learn about this selective growth hormone secretagogue, its mechanisms, research applications, purity, and Peptides Pharma's vial system.
10 questionsPRODUCTTirzepatide research FAQ. Learn about dual GIP/GLP-1 agonist mechanisms, metabolic research, purity, dosing, and Peptides Pharma's peptide vial system.
10 questionsPRODUCTGHK-Cu copper peptide FAQ. Learn about collagen synthesis, skin repair mechanisms, anti-aging research, purity, and Peptides Pharma's lyophilized vial format.
10 questionsPRODUCTGlutathione research FAQ. Learn about this master antioxidant, detoxification mechanisms, immune support research, purity, and Peptides Pharma's vial system.
10 questionsOur team is here to help. Contact us for expert guidance on peptide research.
